Table 3.
sFlt1/PlGF tertile and risk of adverse outcome in all participants and those presenting at less than 34 weeks gestation
| All | Tertile 1 (n=205, S/P≤9.7) |
Tertile 2 (N=206, 9.7<S/P<39.2) |
Tertile 3 (n=205, S/P≥39.2) |
|||||
|---|---|---|---|---|---|---|---|---|
| N | Adverse Outcomes |
Adverse Outcomes |
OR (95% CI) | Adverse Outcomes |
OR (95% CI) | Adverse Outcomes |
OR (95% CI) | |
| All Participants | 616 | 268 (43.5%) | 43 (21.0%) | Ref | 78 (37.9%) | 2.3 (1.5, 3.6) | 147 (71.7%) | 9.5 (6.1, 15.0) |
| Normotensive | 280 | 73 (26.1%) | 18 (14.8%) | Ref | 28 (26.7%) | 2.1 (1.1, 4.1) | 27 (50.9%) | 6.0 (2.9, 12.5) |
| Non-Proteinuric | 183 | 138 (31.9%) | 28 (16.4%) | Ref | 52 (32.1%) | 2.4 (1.4, 4.1) | 58 (58.0%) | 7.1 (4.0, 12.4) |
| Presenting at <34 Weeks | Tertile 1 (n=58, S/P≤4.2) | Tertile 2 (N=59, 4.2<S/P<40.5) | Tertile 3 (n=59, S/P≥40.5) | |||||
| N | Adverse Outcomes | Adverse Outcomes | OR (95% CI) | Adverse Outcomes | OR (95% CI) | Adverse Outcomes | OR (95% CI) | |
| All Participants | 176 | 59 (33.5%) | 4 (6.9%) | Ref | 9 (15.3%) | 2.4 (0.7, 8.4) | 46 (78.0%) | 47.8 (14.6, 156.6) |
| Normotensive | 76 | 11 (14.5%) | 2 (5.3%) | Ref | 2 (7.4%) | 1.4 (0.2, 10.9) | 7 (63.6%) | 31.5 (4.8, 206.6) |
| Non-Proteinuric | 113 | 18 (15.9%) | 0 (0.0%) | Ref* | 5 (10.2%) | Ref* | 13 (61.9%) | 28.3 (8.0, 99.7) |
Adverse outcomes were considered if they occurred within 2 weeks of presentation. S/P= sFlt1/PlGF ratio. Sample sizes and percents for each tertile represent the number of adverse outcomes and the percent of adverse outcomes from all those classified in a tertile.
*
In non-proteinuric participants presenting at less than 34 weeks, the reference odds ratio is the incidence of adverse outcome in tertiles 1 and 2 combined.